Ondansetron vs Oxandrolone
FDA Approved vs Well Studied
avoid Mechanism-based · 64% Both Ondansetron and Oxandrolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Ondansetron Oxandrolone
Weight 293.36 Da 306.44 Da
Half-life ~4 hours ~9-10 hours
Type Carbazole derivative (C18H19N3O) 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
Ondansetron
01 Highly effective at controlling nausea and vomiting from a wide range of causes, including GLP-1 agonists, HCG, and nandrolone
02 Orally disintegrating tablet (ODT) dissolves on the tongue in seconds, ideal for use during active nausea when swallowing pills is difficult
03 Does not cause sedation, extrapyramidal symptoms, or prolactin elevation, unlike dopamine-blocking anti-emetics
04 Fast onset of action (15-30 minutes oral, near-immediate for ODT) with reliable 4-8 hour duration
05 Well-tolerated with a mild side effect profile at standard doses
06 Widely available as an inexpensive generic in multiple formulations
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Side Effects
Ondansetron
Headache (most frequently reported side effect)
Constipation (5-HT3 blockade reduces gut motility)
Fatigue or dizziness
Dry mouth
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
Known hypersensitivity to ondansetron or other 5-HT3 antagonists
Congenital long QT syndrome
Concurrent use of apomorphine (risk of severe hypotension and loss of consciousness)
Severe hepatic impairment (maximum dose should not exceed 8 mg/day)
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
Ondansetron Oxandrolone
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest — September 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.